Back to top
more

Assertio (ASRT)

(Delayed Data from NSDQ)

$0.84 USD

0.84
325,501

+0.01 (0.85%)

Updated Oct 13, 2025 04:00 PM ET

After-Market: $0.84 0.00 (-0.25%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.81%
2Buy17.98%
3Hold9.90%
4Sell5.43%
5Strong Sell2.74%
S&P50011.32%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (77 out of 243)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Is Assertio (ASRT) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Encompass Health (EHC) Opens EHR-Backed Hospital in Florida

by Zacks Equity Research

Encompass Health (EHC) takes its U.S. inpatient rehabilitation hospital count to 150 with the opening of a hospital in Florida integrated with the sound EHR system of Oracle Cerner.

Zacks Equity Research

New Strong Buy Stocks for June 21st

by Zacks Equity Research

IMO, ASRT, LPX, EGLE, and CAL have been added to the Zacks Rank #1 (Strong Buy) List on June 21, 2022.

Zacks Equity Research

Assertio (ASRT) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Assertio (ASRT) closed the most recent trading day at $2.78, moving +0.72% from the previous trading session.

Zacks Equity Research

Has Assertio (ASRT) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Assertio (ASRT) and Savara Inc. (SVRA) have performed compared to their sector so far this year.

Zacks Equity Research

Humana (HUM) to Offer Home Care Model to Virginia's MA Members

by Zacks Equity Research

Humana (HUM) expands the customer reach of its unit's value-based home care model to Virginia, with an aim to offer better in-home care services to the state's Medicare Advantage members.

Zacks Equity Research

ASRT vs. ZTS: Which Stock Is the Better Value Option?

by Zacks Equity Research

ASRT vs. ZTS: Which Stock Is the Better Value Option?

Zacks Equity Research

Assertio (ASRT) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Assertio (ASRT) closed at $3.11 in the latest trading session, marking a +1.63% move from the prior day.

Zacks Equity Research

Best Momentum Stocks to Buy for June 10th

by Zacks Equity Research

ASRT, TTI and HCI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 10, 2022.

Zacks Equity Research

New Strong Buy Stocks for June 10th

by Zacks Equity Research

SBLK, SSB, HCI, ASRT, and TTI have been added to the Zacks Rank #1 (Strong Buy) List on June 10, 2022.

Zacks Equity Research

Anthem (ANTM) Up 27% in a Year: Can It Retain the Momentum?

by Zacks Equity Research

Anthem (ANTM) is well-poised for growth on sustained top-line improvement, membership increases in Government business and sturdy financial position.

Zacks Equity Research

Best Momentum Stocks to Buy for June 7th

by Zacks Equity Research

SBLK, ASRT and GOGL made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 7, 2022.

Zacks Equity Research

New Strong Buy Stocks for June 7th

by Zacks Equity Research

SBLK, GOGL, LPX, ASRT, and CC have been added to the Zacks Rank #1 (Strong Buy) List on June 7, 2022.

Zacks Equity Research

Are Medical Stocks Lagging Assertio (ASRT) This Year?

by Zacks Equity Research

Here is how Assertio (ASRT) and UnitedHealth Group (UNH) have performed compared to their sector so far this year.

Zacks Equity Research

ASRT vs. ZTS: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

ASRT vs. ZTS: Which Stock Is the Better Value Option?

Zacks Equity Research

Tenet Healthcare (THC) Unit Conifer Offers Services to Brookwood

by Zacks Equity Research

Tenet Healthcare's (THC) unit Conifer inks an agreement with Brookwood Baptist Health to deliver enhanced revenue cycle services to four of the remaining hospitals of the latter across Central Alabama.

Zacks Equity Research

Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Assertio (ASRT) and Sensus Healthcare, Inc. (SRTS) have performed compared to their sector so far this year.

Zacks Equity Research

Assertio (ASRT) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Assertio (ASRT) delivered earnings and revenue surprises of 122.22% and 10.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Assertio (ASRT) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Assertio (ASRT) closed at $2.23 in the latest trading session, marking a +1.36% move from the prior day.

Zacks Equity Research

Assertio (ASRT) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On Assertio Holdings' (ASRT) Q1 earnings call, investors will focus on the sales performance of its marketed products.

Zacks Equity Research

INmune (INMB) Begins Dosing in Mid-Stage Study With AD Candidate

by Zacks Equity Research

INmune (INMB) doses the first patient in a phase II study with its investigational TNF inhibitor to treat Alzheimer's disease. Stock rises more than 12% post this announcement.

Zacks Equity Research

Is Assertio (ASRT) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Assertio (ASRT) and Histogen Inc (HSTO) have performed compared to their sector so far this year.

Zacks Equity Research

Actinium (ATNM) Up on Commercialization Deal With Immedica

by Zacks Equity Research

Actinium (ATNM) out-licenses exclusive rights to Iomab-B, an antibody radiation conjugate for facilitating bone-marrow transplant, to Immedica in Europe, the Middle East and North African countries.

Zacks Equity Research

Best Value Stocks to Buy for April 13th

by Zacks Equity Research

WFG, GOGL, and ASRT made it to the Zacks Rank #1 (Strong Buy) value stocks list on April 13, 2022.

Zacks Equity Research

Aerie (AERI) Expands Market Presence Despite Stiff Competition

by Zacks Equity Research

Aerie (AERI) is progressing well with the development of its ophthalmology pipeline. Its partnership with Santen Pharmaceuticals allows it to expand the presence of its drugs outside the United States.